Uppsala, Sweden

Per Erik Andrén

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Per Erik Andrén. Retrieved from https://idiyas.com/inventor/per-erik-andrandeacuten

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,570 
Other
 patents

Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Per Erik Andrén: Innovator in Medicinal Chemistry

Introduction

Per Erik Andrén is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that affect the dopaminergic system.

Latest Patents

Andrén holds a patent for "2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use." This invention relates to a class of compounds characterized by a general formula that includes various substituents, which can be tailored for specific medicinal applications. The compounds are designed to have effects on the central nervous system and circulation, making them valuable in pharmaceutical formulations.

Career Highlights

Throughout his career, Andrén has focused on the synthesis and application of innovative chemical compounds. His work has contributed to advancements in the development of new medications aimed at treating disorders related to the dopaminergic system.

Collaborations

Andrén has collaborated with notable colleagues, including Håkan Vilhelm Wikström and Per Arvid Emil Carlsson. These partnerships have fostered a collaborative environment that enhances research and innovation in medicinal chemistry.

Conclusion

Per Erik Andrén's contributions to the field of medicinal chemistry, particularly through his patented inventions, highlight his role as an influential inventor. His work continues to impact the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…